Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 355

1.

Absence of CALR Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels.

Catherwood MA, Graham A, Cuthbert RJG, Garrec C, Gardie B, Girodon F, Laird S, Cross NCP, McMullin MF.

Acta Haematol. 2018 May 30;139(4):217-219. doi: 10.1159/000489006. [Epub ahead of print] No abstract available.

PMID:
29847812
2.

Chronic neutrophilic leukemia.

Khoder A, Al Obaidi M, Babb A, Liu C, Cross NCP, Bain BJ.

Am J Hematol. 2018 Jun;93(6):841-842. doi: 10.1002/ajh.25073. Epub 2018 Mar 14. No abstract available.

PMID:
29473201
3.

Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia.

Hoade Y, Metzgeroth G, Schwaab J, Reiter A, Cross NCP.

Acta Haematol. 2018;139(2):71-73. doi: 10.1159/000485959. Epub 2018 Jan 26. No abstract available.

PMID:
29393093
4.

Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.

Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018 Feb 19.

PMID:
29341334
5.

A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).

Ghazzawi M, Mehra V, Knut M, Brown L, Tapper W, Chase A, de Lavallade H, Cross NCP.

Acta Haematol. 2017;138(4):198-200. doi: 10.1159/000484077. Epub 2017 Nov 24. No abstract available.

6.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF.

Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.

PMID:
29074595
7.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96202. Epub 2017 Sep 1. No abstract available.

8.

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.

Jawhar M, Naumann N, Knut M, Score J, Ghazzawi M, Schneider B, Kreuzer KA, Hallek M, Drexler HG, Chacko J, Wallis L, Fabarius A, Metzgeroth G, Hofmann WK, Chase A, Tapper W, Reiter A, Cross NCP.

Leukemia. 2017 Oct;31(10):2271-2273. doi: 10.1038/leu.2017.240. Epub 2017 Jul 28. No abstract available.

9.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.

Ann Hematol. 2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.

PMID:
28725989
10.

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T.

Leukemia. 2017 Sep;31(9):1936-1943. doi: 10.1038/leu.2017.190. Epub 2017 Jun 19.

PMID:
28626218
11.

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis.

Defour JP, Hoade Y, Reuther AM, Callaway A, Ward D, Chen F, Constantinescu SN, Cross NCP.

Leukemia. 2017 Aug;31(8):1838-1839. doi: 10.1038/leu.2017.153. Epub 2017 May 22. No abstract available.

PMID:
28529309
12.

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.

Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP.

Cancer. 2017 Jul 15;123(14):2680-2687. doi: 10.1002/cncr.30679. Epub 2017 May 18.

PMID:
28518222
13.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Jun 1;127(6):2206-2221. doi: 10.1172/JCI91363. Epub 2017 Apr 24.

14.

Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.

Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A.

Blood. 2017 Jul 13;130(2):137-145. doi: 10.1182/blood-2017-01-764423. Epub 2017 Apr 19.

15.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

16.

Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera.

Silver RT, Krichevsky S, Gjoni S, Cross NCP.

Leuk Lymphoma. 2017 Nov;58(11):2768-2769. doi: 10.1080/10428194.2017.1300892. Epub 2017 Mar 20. No abstract available.

PMID:
28317411
17.

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, Harrison CN.

Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16. No abstract available.

18.

Genomics of Myeloproliferative Neoplasms.

Zoi K, Cross NC.

J Clin Oncol. 2017 Mar 20;35(9):947-954. doi: 10.1200/JCO.2016.70.7968. Epub 2017 Feb 13. Review.

PMID:
28297629
19.

Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.

Scott S, Travis D, Whitby L, Bainbridge J, Cross NCP, Barnett D.

Br J Haematol. 2017 May;177(3):414-422. doi: 10.1111/bjh.14557. Epub 2017 Mar 14.

PMID:
28295199
20.

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.

Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A.

Haematologica. 2017 Jun;102(6):1035-1043. doi: 10.3324/haematol.2017.163964. Epub 2017 Mar 2.

21.

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.

Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, Rea D, Castagnetti F, Hellmann A, Rosti G, Gattermann N, Coronel MLP, Gutierrez MAE, Garcia-Gutierrez V, Vincenzi B, Dezzani L, Giles FJ.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.

22.

Guideline for the investigation and management of eosinophilia.

Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology.

Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488. Epub 2017 Jan 23. No abstract available.

23.

Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators.

Ruiz MS, Medina M, Tapia I, Mordoh J, Cross NC, Larripa I, Bianchini M.

Leukemia. 2016 Nov;30(11):2258-2260. doi: 10.1038/leu.2016.197. Epub 2016 Jul 25. No abstract available.

24.

Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene.

Kralovicova J, Moreno PM, Cross NC, Pêgo AP, Vorechovsky I.

Nucleic Acid Ther. 2016 Dec;26(6):392-400. Epub 2016 Sep 22.

25.

Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.

Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, Horny HP, Sotlar K, Schoenberg SO, Cross NC, Fabarius A, Hofmann WK, Valent P, Metzgeroth G, Reiter A.

Leukemia. 2016 Dec;30(12):2342-2350. doi: 10.1038/leu.2016.190. Epub 2016 Jul 15.

PMID:
27416984
26.

Deep molecular response in chronic myeloid leukemia.

Cross NC, Hochhaus A.

Leukemia. 2016 Jul;30(7):1632. doi: 10.1038/leu.2016.78. Epub 2016 May 13. No abstract available.

PMID:
27174492
27.

Corrigendum: Exon-centric regulation of ATM expression is population-dependent and amenable to antisense modification by pseudoexon targeting.

Kralovicova J, Knut M, Cross NC, Vorechovsky I.

Sci Rep. 2016 May 9;6:25256. doi: 10.1038/srep25256. No abstract available.

28.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S.

Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25.

29.

Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.

Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, Valent P, Cross NC, Hofmann WK, Metzgeroth G, Reiter A.

Eur J Clin Invest. 2016 May;46(5):392-7. doi: 10.1111/eci.12607. Epub 2016 Mar 21.

PMID:
26914980
30.

Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.

Schwaab J, Jawhar M, Naumann N, Schmitt-Graeff A, Fabarius A, Horny HP, Cross NC, Hofmann WK, Reiter A, Metzgeroth G.

Ann Hematol. 2016 Mar;95(4):557-62. doi: 10.1007/s00277-016-2598-x. Epub 2016 Jan 22.

PMID:
26797429
31.

Exon-centric regulation of ATM expression is population-dependent and amenable to antisense modification by pseudoexon targeting.

Kralovicova J, Knut M, Cross NC, Vorechovsky I.

Sci Rep. 2016 Jan 6;6:18741. doi: 10.1038/srep18741. Erratum in: Sci Rep. 2016 May 09;6:25256.

32.

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A.

Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14.

PMID:
26464169
33.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brümmendorf TH, Porkka K, Saglio G, Gastl G, Müller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ.

Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. Epub 2015 Oct 6.

34.

Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.

Naumann N, Schwaab J, Metzgeroth G, Jawhar M, Haferlach C, Göhring G, Schlegelberger B, Dietz CT, Schnittger S, Lotfi S, Gärtner M, Dang TA, Hofmann WK, Cross NC, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2015 Dec;54(12):762-70. doi: 10.1002/gcc.22287. Epub 2015 Sep 10.

PMID:
26355392
35.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF.

Haematologica. 2015 Sep;100(9):1117-30. doi: 10.3324/haematol.2014.114660.

36.

Constitutional genetic association with CALR mutations?

Eder-Azanza L, Evans P, Wickham C, Akiki S, Vizmanos JL, Chase A, Cross NC.

Leukemia. 2015 Dec;29(12):2410-1. doi: 10.1038/leu.2015.186. Epub 2015 Jul 22. No abstract available.

PMID:
26198293
37.

Neutrophilic leukemoid reaction in multiple myeloma.

Milojkovic D, Hunter A, Barton L, Cross NC, Bain BJ.

Am J Hematol. 2015 Nov;90(11):1090. doi: 10.1002/ajh.24106. No abstract available.

38.

Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus.

Chase A, Leung W, Tapper W, Jones AV, Knoops L, Rasi C, Forsberg LA, Guglielmelli P, Zoi K, Hall V, Chiecchio L, Eder-Azanza L, Bryant C, Lannfelt L, Docherty L, White HE, Score J, Mackay DJ, Vannucchi AM, Dumanski JP, Cross NC.

Leukemia. 2015 Oct;29(10):2069-74. doi: 10.1038/leu.2015.130. Epub 2015 May 20.

39.

KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.

Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K, Horny HP, Gaiser T, Hofmann WK, Schnittger S, Cross NC, Fabarius A, Reiter A.

Am J Hematol. 2015 Sep;90(9):774-7. doi: 10.1002/ajh.24075. Epub 2015 Aug 14.

40.

Response to Ho-Wan Ip and Chi-Chiu.

Cross NC, Müller MC, Hochhaus A.

Leukemia. 2015 Jul;29(7):1619. doi: 10.1038/leu.2015.97. Epub 2015 May 22. No abstract available.

PMID:
25999150
41.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC.

Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.

42.

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization.

Cross NC, Hochhaus A, Müller MC.

Ann Hematol. 2015 Apr;94 Suppl 2:S219-25. doi: 10.1007/s00277-015-2315-1. Epub 2015 Mar 27. Review.

PMID:
25814088
43.

Identification of U2AF(35)-dependent exons by RNA-Seq reveals a link between 3' splice-site organization and activity of U2AF-related proteins.

Kralovicova J, Knut M, Cross NC, Vorechovsky I.

Nucleic Acids Res. 2015 Apr 20;43(7):3747-63. doi: 10.1093/nar/gkv194. Epub 2015 Mar 16.

44.

Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Winkelmann N, Rose-Zerilli M, Forster J, Parry M, Parker A, Gardiner A, Davies Z, Steele AJ, Parker H, Cross NC, Oscier DG, Strefford JC.

Haematologica. 2015 Jun;100(6):e237-9. doi: 10.3324/haematol.2014.120238. Epub 2015 Feb 20. No abstract available.

45.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A.

Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5. Review.

46.

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, Kristensen TK, Kluin-Nelemans HC, Hermine O, Dubreuil P, Sperr WR, Hartmann K, Gotlib J, Cross NC, Haferlach T, Garcia-Montero A, Orfao A, Schwaab J, Triggiani M, Horny HP, Metcalfe DD, Reiter A, Valent P.

Leukemia. 2015 Jun;29(6):1223-32. doi: 10.1038/leu.2015.24. Epub 2015 Feb 4. Review.

47.

Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals.

Score J, Chase A, Forsberg LA, Feng L, Waghorn K, Jones AV, Rasi C, Linch DC, Dumanski JP, Gale RE, Cross NC.

Leukemia. 2015 Jul;29(7):1600-2. doi: 10.1038/leu.2015.13. Epub 2015 Jan 28. No abstract available.

PMID:
25627638
48.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF; MDS/MPN International Working Group.

Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26.

49.

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J.

Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901.

50.

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, Müller N, Schneider S, Naumann N, Walz C, Haferlach T, Valent P, Hofmann WK, Cross NC, Fabarius A, Reiter A.

Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.

PMID:
25567135

Supplemental Content

Loading ...
Support Center